Brian Greet, MD
Clinical Cardiac Electrophysiology · Houston, TXNPI 1891011573
Payments from drug & device makers
Across 810 payments — averaging $63.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$16K
- Abbott$11K
- Medical Device Business Services, Inc.$10K
- Medtronic$9K
- Boston Scientific$2K
- Irhythm Technologies, Inc.$449
- plus $3K from 24 others
What the payments were for
- Consulting fees$13,50026%
- Speaking & faculty fees$5,55011%
- Grants$1,2502%
- Travel & lodging$1,8764%
- Food & beverage$29,49457%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 388 | $16,135 |
| Abbott | 146 | $11,027 |
| Medical Device Business Services, Inc. | 7 | $9,750 |
| Medtronic(2 entities) | 83 | $8,766 |
| Boston Scientific | 44 | $2,411 |
| Irhythm Technologies, Inc. | 34 | $449 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $397 |
| Johnson & Johnson(2 entities) | 19 | $380 |
| Baxter Healthcare | 10 | $287 |
| Biotronik Inc. | 7 | $259 |
| Impulse Dynamics (USA) Inc. | 3 | $212 |
| E.r. Squibb & Sons, L.L.C. | 15 | $200 |
| ZOLL Respicardia, Inc. | 2 | $179 |
| Cardiva Medical, Inc. | 7 | $178 |
| Abiomed | 1 | $134 |
| Pfizer | 6 | $126 |
| Novartis | 6 | $122 |
| Cardiofocus, Inc. | 1 | $98 |
| Shockwave Medical, Inc | 2 | $95 |
| Sanofi-aventis U.S. LLC | 4 | $88 |
| Angiodynamics, Inc. | 1 | $75 |
| Altathera Pharmaceuticals LLC | 4 | $75 |
| Actelion Pharmaceuticals US, Inc. | 3 | $63 |
| Cvrx, Inc. | 2 | $38 |
| Amgen | 2 | $27 |
| Sanofi | 1 | $22 |
| Elutia, Inc. | 1 | $22 |
| Portola Pharmaceuticals, LLC | 1 | $20 |
| Saranas, Inc. | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$16,653
- GENERAL BRADY$1,250
- AVEIR$1,166
- Quadra Assura CRT Defibrillator$1,027
- Accent Pacemaker$829
- Assurity Pacemaker$754
- Fortify Assura, Ellipse ICD$661
- EnSite Precision Cardiac Mapping System$625
- Confirm Rx$577
- Carto 3 System$570
- Durata Defibrillation ICD Lead$367
- OPTIMIZER$325
- QUADRA ASSURA$308
- Ensite Cardiac Mapping System$305
- Merlin Connectivity and Remote$291
- OCTARAY MAPPING CATHETER$256
- Agilis HisPro$172
- CardioMEMS HF System$169
- TENDRIL$166
- ALLURE QUADRA$162
How this compares
$51,670 in reported general payments places this provider in the 55th percentile of 233 clinical cardiac electrophysiology providers in Texas.
See all clinical cardiac electrophysiology providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $169,962 |
| XareltoRivaroxaban | 36 | $33,446 |
| Flecainide Acetate | 105 | $4,800 |
| Amiodarone Hcl | 111 | $2,495 |
| Metoprolol Succinate | 68 | $1,089 |
| Colchicine | 99 | $839 |
| SotalolSotalol Hcl | 23 | $603 |
| Metoprolol Tartrate | 72 | $541 |
| Minocycline Hcl | 55 | $399 |
| Pantoprazole Sodium | 68 | $214 |
| ClopidogrelClopidogrel Bisulfate | 13 | $166 |
| Bumetanide | 13 | $107 |
| Furosemide | 15 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $169,962148 claims |
| Johnson & JohnsonXarelto | $380 | $33,44636 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 233 clinical cardiac electrophysiology providers in Texas.
Other clinical cardiac electrophysiology in Houston
- Miguel ValderrabanoHouston$1.3M
- Ramesh HariharanHouston$793K
- Abdi RasekhHouston$728K
- Amir AzeemHouston$488K
- Mehdi RazaviHouston$390K
- Ilyas ColombowalaHouston$362K
- Ijeoma EkeruoHouston$353K
- John SegerHouston$300K
- Mihail CheluHouston$256K
- Jie ChengHouston$176K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.